Curevo, a Seattle-based biotech startup developing a vaccine against shingles, raised $110 million in a Series B round.

Daily aspirin use after standard adjuvant therapy did not improve DFS for patients with colorectal cancer, according to ...

Subcutaneous administration of trastuzumab and pertuzumab significantly shortened the time patients with stage I ...

Adjuvant CRT did not improve outcomes over adjuvant RT in patients with intermediate-risk, early-stage cervical cancer after radical hysterectomy.

In its effort to rival GSK’s shingles vaccine Shingrix, Curevo Vaccine has circled up $110 million and recruited two former ...

Results from the NRG Oncology GOG-0263 Phase III clinical trial testing the addition of cisplatin-based chemotherapy to ...

Neoadjuvant nivolumab has demonstrated efficacy in patients with mismatch repair-deficient, surgically resectable endometrial cancer.

A large-scale, international, multicentre, phase 3 clinical trial of aspirin for the secondary prevention of colorectal ...

An expert discusses how the updated results from CheckMate 274 (Galsky 2025) include updated disease-free survival (DFS) and interim overall survival (OS), along with other key end points such as ...

Results from the NRG Oncology GOG-0263 phase III clinical trial testing the addition of cisplatin-based chemotherapy to ...